Skip to main content

Table 1 Clinical characteristics of the 167 patients with initial diagnosis of NMIBC

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

Characteristic

Case (n = 167)

Control (n = 105)

Age, yrs.

 Median

67

53

 Range

28–85

23–81

Sex, no. (%)

 Male

135 (80.8)

52 (49.5)

 Female

32 (19.2)

53 (50.5)

Smoking History, no. (%)

 Current smoker

38 (22.8)

NA

 Former smoker

58 (34.7)

NA

 Non-smoker

67 (40.1)

NA

 Missing

4 (2.4)

 

Cytology, no. (%)

 Negative/Positive/Suspicious

123 (73.6)/8 (4.8)/6 (3.6)

105 (100)

 Missing

30 (18.0)

 

Tumor Stage, no. (%)

 pTa/pT1/CIS

126 (75.4)/25 (15.0)/6 (3.6)

NA

 Other

10 (6.0)

NA

Tumor Grade, no. (%)

 Low/High

100 (59.9)/67 (40.1)

NA

Risk Categories, no. (%)

 Low/Intermediate/High

40 (24.0)/56 (33.5)/71 (42.5)

NA